Pilot Tam>Femara or AI Age 40s ES/LA BC
Pilot Study of Femara or Other Aromatase Inhibitors in Women in Their 40s with Early Stage or Locally Advanced Breast Cancer Who Have Ceased Menstruating with Adjuvant Chemotherapy.

Preop Herc ± Lap vs Lap HER2+ BrCa
Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with ErbB2- (HER2/neu-) Overexpressing Invasive Breast Cancer.

TAC vs. TC for Adjuvant Breast Ca
Phase III Trial of Adjuvant TC versus TAC in Early Stage HER2-Negative Breast Cancer Patients.

Ixabepilone Q1W vs Q3W Met Br
CaPhase II Randomized Trial of Weekly and Every 3-week Ixabepilone in Metastatic Breast Cancer (MBC) Patients.

Yondelis Trip Neg MBC or HER2 O/Exp BrCa
Phase II, Multi-center, Open-label, clinical trial of Trabectedin (Yondelis®) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-), HER2 overexpressing tumors and BRCA1 or BRCA2 mutation carriers.

Gem/Carbo ± Avastin Plat Sens Ov Ca
A Phase III, Multi-center, Randomized, Blinded, Placebocontrolled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma.

Docetaxel+Oxali±Cetux Met Gastric/GEJ
Phase II trial of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma.

PNH level viaCD59 on RBC,WBC; BM Failure
Examination of PNH, by Level Of CD59 on red and white blood cells, in bone marrow failure syndromes (EXPLORE).

FCR vs PCR in untx'd & tx'd CLL
A Prospective, Randomized, Open-label, Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in previously untreated or treated b-cell chronic lymphocytic leukemia.

Docetaxel or Alimta+/-Erbitux 2Ln NSCLC
Randomized Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-small Cell Lung Cancer after Platinumbased Therapy (IMCL CP02-0452).

Hypo Meth Agent +/- AMG531 for MDS Pts
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Subjects with Low or Intermediate Risk Myelodysplastic Syndrome (MDS) Receiving Hypomethylating Agents.
Lenalidomide +/- AMG531 in MDS
A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AMG 531 Treatment of Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Receiving Lenalidomide (20060102).
MORE: Non-Interv Registry Lower-Risk MDS
A Prospective, Non-interventional Multi-center Registry in Iron Overloaded Lower-Risk Myelodysplastic Patients.

VelThalDex v VelDex v VelMelPred 1ln MM
Randomized Phase IIIb Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation:
VELCADE® (Bortezomib), Thalidomide, and Dexamethasone
(VTD) versus VELCADE® and Dexamethasone (VD) versus
VELCADE®, Melphalan, and Prednisone (VMP) (UPFRONT).

Gem/Carbo ± Avastin Plat Sens Ov Ca
A Phase III, Multi-center, Randomized, Blinded, Placebocontrolled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma.

Gem/Carbo ± Avastin Plat Sens Ov Ca
A Phase III, Multi-center, Randomized, Blinded, Placebocontrolled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma.

Mitoxantrone ± Cetuximab 2nd line AIPC
A Randomized Phase II study of mitoxantrone vs. mitoxantrone with cetuximab in metastatic androgen independent prostate cancer (AIPC) previously treated with docetaxel-based chemotherapy.

MORE: Non-Interv Registry Lower-Risk MDS
A Prospective, Non-Interventional Multi-center Registry in Iron Overloaded Lower-Risk Myelodysplastic Patients.